EP3305295A1 - Médicament aqueux - Google Patents

Médicament aqueux Download PDF

Info

Publication number
EP3305295A1
EP3305295A1 EP16803454.4A EP16803454A EP3305295A1 EP 3305295 A1 EP3305295 A1 EP 3305295A1 EP 16803454 A EP16803454 A EP 16803454A EP 3305295 A1 EP3305295 A1 EP 3305295A1
Authority
EP
European Patent Office
Prior art keywords
compound
liquid formulation
aqueous liquid
solution
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16803454.4A
Other languages
German (de)
English (en)
Other versions
EP3305295A4 (fr
Inventor
Takahiro Goto
Hitoshi Kozuka
Mizuho SHIBATA
Wataru Minagawa
Norihiro Kanayama
Chifuyu TORIUMI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Publication of EP3305295A1 publication Critical patent/EP3305295A1/fr
Publication of EP3305295A4 publication Critical patent/EP3305295A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to an aqueous liquid formulation. More specifically, the present invention relates to an aqueous liquid formulation including a solution that contains a compound represented by general formula (1) (hereinafter, also referred to as a compound of formula (1)) or a salt thereof, and a magnesium compound.
  • a compound represented by general formula (1) hereinafter, also referred to as a compound of formula (1)
  • a magnesium compound hereinafter, also referred to as a compound of formula (1)
  • R 1 represents an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more substituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group, or a hydroxyl group
  • R 2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group or an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more substituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group or a hydroxyl group
  • R 3 represents a hydrogen atom or a halogen atom
  • R 4 represents a hydrogen atom or a halogen atom
  • X represents a halogen atom.
  • a 7-[4-substituted-3- ⁇ (cyclopropylamino)methyl ⁇ -1-pyrrolidinyl]q uinolone carboxylic acid derivative not only is safe and has a strong antibacterial activity, but also exhibits a strong antibacterial activity to resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant Enterococcus (VRE) (Patent Literature 1).
  • MRSA methicillin-resistant Staphylococcus aureus
  • PRSP penicillin-resistant Streptococcus pneumoniae
  • VRE vancomycin-resistant Enterococcus
  • Patent Literatures 2 to 7 disclose an aqueous liquid formulation in which a quinolone carboxylic acid derivative is contained as a principal agent and which is neutral pH. These literatures disclose a formulation in which the precipitation of the principal agent is suppressed and the principal agent is solubilized by adding polyvalent metal such as magnesium into a solution (Patent Literatures 2 to 7).
  • Patent Literature 9 discloses a formulation which includes a lyophilized formulation containing quinolone carboxylic acid and a dilution liquid containing a polyvalent metal compound.
  • An object is to provide a novel aqueous liquid formulation that contains a compound of formula (1) or a salt thereof, in which the chemical decomposition of the compound of the formula (1) or a salt thereof is inhibited.
  • the present inventors intensively conducted research on the preparation of the aqueous liquid formulation that contains the compound of the formula (1) or a salt thereof. As a result, they determined that the cyclopropylaminomethyl structure contained in the compound of the formula (1) is likely to be chemically decomposed, causing the generation of a compound represented by general formula (2) (hereinafter, also referred to as a "compound of formula (2)") in which a cyclopropyl group is detached.
  • R 1 , R 2 , R 3 and X are defined as described above.
  • the present inventors have found that precipitation of the compound of the formula (1) or a salt thereof and decomposition of the compound of the formula (1) can be inhibited by adjusting pH of the solution containing particular amounts of the compound of the formula (1) or a salt thereof and the magnesium compound within a specific pH range, and completed the present invention.
  • an aqueous liquid formulation that contains the compound of the formula (1) or a salt thereof, in which the precipitation of the compound of the formula (1) or a salt thereof and the decomposition of the compound of the formula (1) are inhibited, can be provided.
  • the present embodiment relates to an aqueous liquid formulation that contains a compound represented by general formula (1) or a salt thereof and a magnesium compound.
  • R 1 represents an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more subastituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group, and a hydroxyl group
  • R 2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group or an alkyl group having 1 to 3 carbon atoms which is optionally substituted with one or more substituents selected from the group consisting of a hydrogen atom, a halogen atom, an amino group, a cyano group or a hydroxyl group
  • R 3 represents a hydrogen atom or a halogen atom
  • R 4 represents a hydrogen atom or a halogen atom
  • X represents a halogen atom
  • the "magnesium compound” described herein is a compound that contains magnesium.
  • the magnesium compound may include an inorganic magnesium salt such as magnesium chloride, magnesium sulfate, magnesium nitrate, and magnesium phosphate, and an organic magnesium salt such as magnesium citrate, magnesium gluconate, magnesium acetate, and magnesium propionate.
  • an inorganic magnesium salt such as magnesium chloride, magnesium sulfate, magnesium nitrate, and magnesium phosphate
  • an organic magnesium salt such as magnesium citrate, magnesium gluconate, magnesium acetate, and magnesium propionate.
  • the magnesium compound may preferably be an inorganic magnesium salt, and particularly preferably magnesium chloride.
  • aqueous liquid formulation is a formulation that contains water as base material and is in the form of liquid. Examples thereof may include an injectable formulation, an ophthalmic liquid drug, aqueous nasal drops, aqueous ear drops, and an inhalant liquid drug.
  • the "injectable formulation” described herein is a sterile formulation to be directly administered to body tissues and organs, such as subcutaneous or intramuscular tissues and blood vessels.
  • the "dilution liquid” described herein is a solvent or solution used for diluting the aqueous liquid formulation, and represents any solvent or solution that is not harmful when administered to a patient.
  • the solvent or solution that can be used as the dilution liquid may include water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and a xylitol liquid.
  • One or more of these solvents and solutions may be used as the dilution liquid.
  • the dilution liquid may be particularly preferably a saline solution.
  • the aqueous liquid formulation according to the present embodiment is preferably diluted with the dilution liquid so that the concentration of the compound of the formula (1) in the aqueous liquid formulation according to the present embodiment becomes 2 mg/mL or less.
  • the concentration of the compound of the formula (1) when administered may be more preferably 0.5 mg/mL or more and 2 mg/mL or less, and further preferably 1 mg/mL or more and 2 mg/mL or less.
  • halogen atom represents a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom. Among these, a fluorine atom is preferable.
  • alkyl group having 1 to 3 carbon atoms described herein represents a methyl group, an ethyl group, a propyl group, or a 2-propyl group.
  • the compound of the formula (1) can be manufactured by, for example, the method described in the WO2005/026147 pamphlet.
  • the compound of the formula (1) contained in the aqueous liquid formulation of the present embodiment may be preferably 7-[3- ⁇ (cyclopropylamino)methyl ⁇ -4-fluoropyrrolidine-1-yl]-6-fl uoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, and further preferably 7-[(3S,4S)-3- ⁇ (cyclopropylamino)methyl ⁇ -4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid.
  • the aqueous liquid formulation of the present embodiment preferably contains a salt of the compound of the formula (1) in terms of the improvement of
  • Examples of the salt of the compound of the formula (1) may include a salt formed with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid, a salt formed with an organic acid such as maleic acid, fumaric acid, succinic acid, malic acid, malonic acid, methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, lactic acid, oxalic acid, acetic acid, trifluoroacetic acid, and tartaric acid, and a salt formed with metal such as sodium, potassium, magnesium, calcium, aluminum, cesium, chromium, cobalt, copper, iron, zinc, platinum, and silver.
  • an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, and phosphoric acid
  • organic acid such as maleic acid, fumaric acid, succinic acid, malic acid, malonic acid, methanesulfonic acid, toluenesulf
  • a hydrochloride may be particularly preferable from the viewpoint of stability.
  • a hydrochloride of 7-[(3S,4S)-3- ⁇ (cyclopropylamino)methyl ⁇ -4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid is excellent as a salt of the compound of the formula (1) contained in the aqueous liquid formulation of the present embodiment, because decomposition by light exposure is suppressed, and chemical decomposition is suppressed even when the storage under accelerated test conditions is performed.
  • the pH of the aqueous liquid formulation of the present embodiment needs to be 5.8 or more and 6.9 or less, in terms of the inhibition of the precipitation of the compound of the formula (1) or a salt thereof during the storage of the aqueous liquid formulation.
  • the aqueous liquid formulation is preferably diluted with the dilution liquid before administered to a patient.
  • the pH of the aqueous liquid formulation of the present embodiment is preferably 5.8 or more and 6.5 or less..
  • the concentration of the compound represented by the formula (1) in the aqueous liquid formulation of the present embodiment may be preferably 3 mg/mL or more, more preferably 5 mg/mL or more, further preferably 10 mg/mL or more, more preferably 10 mg/mL or more and 100 mg/mL or less, particularly preferably 15 mg/mL or more and 90 mg/mL or less, and still further preferably 15 mg/mL or more and 50 mg/mL or less.
  • the specific concentration of the compound represented by the formula (1) in the aqueous liquid formulation of the present embodiment may be, for example, 20 mg/mL, 30 mg/mL, or 40 mg/mL.
  • concentration of the compound represented by the formula (1) in the aqueous liquid formulation is a value obtained by dividing the weight (mg) of the compound of the formula (1) contained in the aqueous liquid formulation by the solvent amount (mL) of the aqueous liquid formulation. It is noted that when a salt of the compound of the formula (1) is used, the above-described “concentration of the compound represented by the formula (1) in the aqueous liquid formulation” is a value obtained by dividing the value (mg) of the weight of the compound of the formula (1) converted from the weight (mg) of the salt of the compound of the formula (1), by the solvent amount (mL).
  • the use amount of the magnesium compound is not particulary limited.
  • the molar ratio of the magnesium compound relative to the compound of the formula (1) or a salt thereof may be preferably 0.35 or more, more preferably 0.40 or more, further more preferably 0.45 or more, and still further more preferably 0.70 or more.
  • the "molar ratio of the magnesium compound relative to the compound of the formula (1) or a salt thereof" may be preferably 3.0 or less, more preferably 1.5 or less, and further more preferably 1.1 or less.
  • the "molar ratio of the magnesium compound relative to the compound of the formula (1) or a salt thereof" is particularly preferably 0.45 or more and 1. 5 or less, and further more preferably 0.70 or more and 1.1 or less.
  • the "pH adjuster" described herein includes an acid, a base, or a buffer.
  • the pH adjuster may include hydrochloric acid, sulfuric acid, adipic acid or a salt thereof, citric acid or a salt thereof, gluconic acid or a salt thereof, succinic acid or a salt thereof, ascorbic acid or a salt thereof, glacial acetic acid or a salt thereof, acetic acid or a salt thereof, tartaric acid or a salt thereof, fumaric acid or a salt thereof, maleic acid or a salt thereof, lactic acid or a salt thereof, malic acid or a salt thereof, phosphoric acid or a salt thereof, glycine, sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, and magnesium hydroxide.
  • pH adjusters one or more of these pH adjusters maybe used.
  • As the pH preferable adjuster hydrochloric acid and sodium hydroxide are examplified. Hydrochloric acid and sodium hydroxide may be more preferable.
  • the pH adjuster the pH can be adjusted within an appropriate range.
  • the content of the compound represented by the formula (1) in the aqueous liquid formulation of the present embodiment is preferably 500 mg or less, further preferably 10 mg or more and 450 mg or less, further preferably 20 mg or more and 400 mg or less, more preferably 30 mg or more and 200 mg or less, and further more preferably 50 mg or more and 160 mg or less.
  • the content of the compound represented by the formula (1), when a salt of the compound represented by the formula (1) is contained, means a value (mg) obtained by converting the weight (mg) of the salt of the compound represented by the formula (1) into the weight of the compound represented by the formula (1).
  • the aqueous liquid formulation of the present embodiment is manufactured by, but not particularly limited to, preferably the method as will be described as a general manufacturing method 1 or the method as will be described as a general manufacturing method 2.
  • a magnesium compound is dissolved in a physiologically acceptable carrier such as water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and a xylitol liquid.
  • a physiologically acceptable carrier such as water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and a xylitol liquid.
  • a pH adjuster is added to the obtained solution.
  • the compound of the formula (1) or a salt thereof is added.
  • the molar ratio of the magnesium compound relative to the compound of the formula (1) or a salt thereof is preferably 0.35 or more, and further preferably 0.45 or more and 1.5 or less.
  • the resultant solution is stir
  • the aqueous liquid formulation of the present embodiment which has a pH of 5.8 or more and 6.9 or less and in which the concentration of the compound represented by the formula (1) is 3 mg/mL or more, can be obtained.
  • the compound of the formula (1) or a salt thereof is dissolved or suspended in a physiologically acceptable carrier such as water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and a xylitol liquid.
  • a physiologically acceptable carrier such as water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and a xylitol liquid.
  • a physiologically acceptable carrier such as water, a saline solution, a Ringer's solution, a glucose solution, a lactate Ringer's solution, an acetate Ringer's solution, a bicarbonate Ringer's solution, a maltose liquid, and
  • the mixture is stirred so that the compound of the formula (1) or a salt thereof is completely dissolved.
  • the pH of the solution may be adjusted by the process of adding a pH adjuster to the solution.
  • the amount of the solution may be adjusted by the process of adding a physiologically acceptable carrier to the solution.
  • the aqueous liquid formulation of the present embodiment which has a pH of 5.8 or more and 6.9 or less and in which the concentration of the compound represented by formula (1) is 3 mg/mL or more, can be obtained.
  • an NMR spectrum was measured using a JNM-EX400 type nuclear magnetic resonance apparatus manufactured by JEOL Ltd. with tetramethyl silane (TMS) as an internal standard.
  • An MS spectrum was measured using JMS-T100LP type and JMS-SX102A type mass spectrometers manufactured by JEOL Ltd.
  • a elemental analysis was performed using a CHN CORDER MT-6 elemental analyzer manufactured by Yanaco Bunseki Kogyo Co.
  • powder X-ray diffraction was performed using RINT2200 manufactured by Rigaku Corporation. Copper radiation was used as radiation.
  • the measurement condition was a tube current of 36 mA, a tube voltage of 40 kV, a divergence slit of 1 degree, a scattering slit of 1 degree, a receiving slit of 0.15 mm, a scan range of 1 to 40 degrees (2 ⁇ ), and a scan rate per minute of 2 degrees (2 ⁇ ).
  • boric acid triacetate adjusting liquid 1.01 kg (16.3 mol) of boric acid (third portion) was added to the mixed liquid, and the mixed liquid was stirred at 24.7 to 27.7°C for 30 minutes. Subsequently, 1.01 kg (16.3 mol) of boric acid (forth portin) was added to the mixed liquid, and the mixed liquid was stirred at 25.4 to 29. 4°C for 30 minutes. Furthermore, the mixed liquid was stirred at 50.0 to 56.9°C for 30 minutes to obtain a boric acid triacetate adjusting liquid.
  • the precipitated crystals were separated by filtration, and washed with 6.93 L of acetone and 13.9 L of diisopropyl ether. Thus, 7.41 kg of wet crystals were obtained.
  • the obtained wet crystals were dried under reduced pressure at a preset temperature of 65.0°C for approximately 20 hours to obtain 6.47 kg of bis(acetato-O)- ⁇ 6,7-difluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo -1,4-dihydroquinoline-3-carboxylato-O 3 ,O 4 ⁇ boron (yield: 90.3%).
  • the reaction liquid was stirred at 23. 7 to 26. 3°C for 2 hours.
  • 120 L of ethyl acetate was added, and 120 L of water was further added.
  • a solution of 960 g (an amount for obtaining 2 mol/L) of sodium hydroxide and 12.0 L of water was added.
  • an aqueous layer was separated.
  • 120 L of ethyl acetate was added.
  • the mixture was stirred for 5 minutes.
  • an ethyl acetate layer was separated.
  • the portions of the ethyl acetate layer were combined, and 120 L of water was added. The mixture was stirred for 5 minutes, and left to stand. Then, an aqueous layer was removed. The ethyl acetate layer was evaporated under reduced pressure. The obtained residue was dissolved in 60.0 L of 2-propanol, and the solution was allowed to stand at room temperature overnigt. A solution of 5.24 L (62.9 mol) of hydrochloric acid and 26.2 L (an amount for obtaining 2 mol/L) of water was added to the obtained 2-propanol solution. The mixed liquid was stirred at 28.2 to 30.0°C for 30 minutes. The mixed liquid was heated at an outer temperature of 55.0°C.
  • the mixed liquid was cooled, resulting in crystallization.
  • the mixed liquid was stirred at 39.9 to 41.0°C for 30 minutes.
  • the resultant product was stirred at 2.2 to 10.0°C for one hour.
  • Precipitated crystals were collected by filtration, and washed with 60 L of 2-propanol to obtain 9.57 kg of wet crude crystals of 7-[(3S,4S)-3- ⁇ (cyclopropylamino)methyl ⁇ -4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid hydrochloride.
  • Precipitated crystals were separated by filtration, and washed with 30.0 L of ethanol to obtain 5.25 kg of wet crystals of 7-[(3S,4S)-3- ⁇ (cyclopropylamino)methyl ⁇ -4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid hydrochloride.
  • the obtained wet crystals were dried under reduced pressure at a preset temperature of 50.0°C for approximately 13 hours to obtain 4.83 kg of the compound (1) (yield: 72.6%).
  • FIG. 1 and 2 The result of the powder X-ray diffraction of the compound (1) based on WO2013/069297 is shown in FIG. 1 and 2 .
  • peaks are observed at 4.9 degrees, 9.8 degrees, 10.8 degrees, 12.9 degrees, 14.7 degrees, 18.2 degrees, 21. 7 degrees, 23.4 degrees, 24.7 degrees, and 26.4 degrees, and characteristic peaks can be confirmed at 4. 9 degrees, 10.8 degrees, 12.9 degrees, 18.2 degrees, 21.7 degrees, 24.7 degrees and 26.4 degrees. Particularly characteristic peaks can be confirmed at 10.8 degrees, 12.9 degrees, and 24.7 degrees.
  • Table 1 Prescription Components Comparative Example 1 Example 1 Example 2 Comparative Example 2 Compound (1) 4.332g 4.332g 4.332g 4.332g Magnesium chloride hexahydrate 920mg 920mg 920mg 0.1 mol/L hydrochloric acid As needed As needed As needed As needed As needed 0.1 mol/L aqueous sodium hydroxide solution As needed As needed As needed As needed As needed Water for injection As needed As needed As needed As needed As needed (Total) 100mL 100mL 100mL 100mL 100mL 100mL (pH) 5.7 5.8 6.9 7.0
  • the aqueous liquid formulation prepared in each of Examples 1 to 2 and Comparative Examples 1 and 2 was measured for the pH and visually observed for appearance. The observation was performed before the storage (that is, immediately after the preparation; the same applies hereinafter) and after the storage of each liquid at 5°C for one week.
  • pH measurement method measured in accordance with the pH measurement method defined in General Test Methods of the Japanese Pharmacopoeia. Observation method: observed using a foreign substance checker (illuminance: 1000 to 2000 lx).
  • Table 2 pH and visual observation result of injectable formulation pH Visual observation result Before storage After storage at 5°C for 1 week Comparative Example 1 5.7 Slightly yellow, clear liquid Precipitation of crystals Example 1 5.8 Slightly yellow, clear liquid Slightly yellow, clear liquid Example 2 6.9 Slightly yellow, clear liquid Slightly yellow, clear liquid Comparative Example 2 7.0 Precipitation of crystals Not performed
  • Example 1 As apparent from the test results shown in Table 2, a white precipitate was observed in Comparative Example 1 having a pH of 5.7 and Comparative Example 2 having a pH of 7.0. However, in Example 1 and Example 2 having a pH of 5.8 to 6.9, a precipitate was not precipitated before and after the storage, and the liquid was slightly yellow and clear.
  • the aqueous liquid formulation prepared in each of Examples 3 to 5 and Comparative Examples 3 to 4 was stored in a constant-temperature bath at 30 ⁇ 2°C for 3 months. After the storage, the content of the compound (1) and the content of the by-product X having an undetermined structure were measured by liquid chromatography (Alliance system, manufactured by Waters). (Condition of Measurement by Liquid Chromatography) Separation column: a stainless tube having an inner diameter of 4.6 mm and a length of 15 cm was filled with octadecyl silylated silica gel with the size of 3 ⁇ m for liquid chromatography.
  • Liquid A a 1000 mL solution obtained by dissolving 2.16 g of sodium 1-octanesulfonate in diluted phosphoric acid (1 ⁇ 1000)
  • Liquid B methanol for liquid chromatography
  • Flow velocity 1.0 mL
  • Detector UV absorptiometer (measurement wavelength: 294 nm)
  • Liquid sending the mixing ratio of liquid A and liquid B is shown in Table 4.
  • Table 4 Table 4: Mixing ratio between liquid A and liquid B Analysis time (minute) Liquid A liquid B 0 ⁇ 32 56 44 32 ⁇ 50 56 ⁇ 30 44 ⁇ 70 50 ⁇ 60 30 70 [Table 5] Table 5: Purity test result Comparative Example 3 Comparative Example 4 Example 3 Example 4 Example 5 Concentration of compound (1) in injectable formulation (mg/mL) 0.5 2.0 4.0 8.0 20 Content rate (%) of by-product X Before storage 0.04 0.04 0.04 0.04 0.04 0.04 0.04 After storage at 30°C for 3 months 0.18 0.16 0.13 0.13 0.11
  • the content rate of the by-product X is shown in Table 5 as the percentage of the content of the by-product X relative to the content of the compound (1).
  • Table 5 As apparent from the results in Table 5, when the concentration of the compound (1) in the aqueous liquid formulation became higher, the content rate of the by-product X after the storage at 30°C for 3 months decreased. Specifically, the content rate of the by-product X was lower in Examples 3 to 5 in which the concentration of the compound (1) was 3 mg/mL or more, compared to those in Comparative Examples 3 and 4 in which the concentration of the compound (1) was less than 3 mg/mL. Furthermore, it can be understood that the generation of the by-product X is further inhibited in Example 5 in which the concentration of the compound (1) is 10 mg/mL or more, compared to Example 3 (4.0 mg/mL) and Example 4 (8.0 mg/mL).
  • the aqueous liquid formulation prepared in each of Examples 6 to 7 and Comparative Example 5 was stored in a constant-temperature bath at 40 ⁇ 2°C for 3 months. After the storage, the content of the compound (1) and the content of the by-product X were measured by liquid chromatography (Alliance system, manufactured by Waters), in the same method as that in Test Example 2.
  • Table 7 Purity test result Components Comparative Example 5
  • Example 6 Concentration of compound (1) in injectable formulation (mg/mL) * 2.0 20 40 Content rate (%) of by-product X Before storage 0.04 0.04 0.04 After storage at 40°C for 3 months 0.45 0.34 0.31 *A value obtained by dividing value (mg) of weight of free form converted from compound (1) by volume (mL) of water for injection
  • the content rate of the by-product X is shown in Table 7 as the percentage of the content of the by-product X relative to the content of the compound (1). As apparent from the results in Table 7, it became clear that when the concentration of the compound (1) became higher, the content rate of the by-product X after the storage at 40°C for 3 months decreased.
  • Table 8 Prescription Components Example 7
  • Example 9 Compound (1) 4.332g 4.332g 4.332g Magnesium chloride hexahydrate 920mg 1.39g 1.85g 0.1 mol/L hydrochloric acid As needed As needed As needed 0.1 mol/L aqueous sodium hydroxide solution As needed As needed As needed As needed Water for injection As needed As needed As needed (Total) 100mL 100mL 100mL (pH) 6.0 6.0 6.0 6.0 6.0
  • the aqueous liquid formulation prepared in each of Examples 7 to 9 was stored in a constant-temperature bath at 40 ⁇ 2°C for 4 weeks. Then, the content of 7- ⁇ (3S,4S)-3-amino methyl-4-fluoropyrrolidine-1-yl ⁇ -6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (the compound (2)) and the content of the compound (1) were measured by liquid chromatography (Alliance system, manufactured by Waters). The liquid chromatography was performed under a condition similar to Test Example 2.
  • the content rate of the compound (2) is shown in Table 9 as the percentage of the content of the compound (2) relative to the content of the compound (1).
  • the generated amount of the compound (2) could be reduced by increasing the content of magnesium chloride in the aqueous liquid formulation to increase the molar ratio of the magnesium compound relative to the compound (1).
  • Example 7 The manufacturing time in each of Example 7, Example 10, and Example 11 was measured. [Table 10] Table 10: Result of manufacturing time for injectable formulation Example 7 Example 10 Example 11 Manufacturing time 56 min 51 min 186 min
  • the manufacturing time in each manufacturing method is shown in Table 10.
  • the compound (1) has the property of being gelled when being brought into contact with water.
  • the compound (1) is added to water as in Example 11, the compound (1) is gelled to become in an unmixed state(lump).
  • stirring needs to be continued for as long as 3 hours until the compound (1) is uniformly mixed with water.
  • manufacturing time becomes longer, manufacturing costs such as abrasion of manufacturing facility and labor costs unfavorably increase.
  • the gelation can be reduced by previously adding magnesium chloride hexahydrate to water to which the compound (1) is to be added and adjusting the pH to a value within an appropriate range.
  • the compound (1) is quickly dissolved in water, and the manufacturing time can be 1/3 or less of that of Example 11.
  • the manufacturing time can also be shortened by heating (Example 10).
  • An aqueous liquid formulation that contains the compound of the formula (1) or a salt thereof, and that has an excellent antibacterial activity against Gram-positive bacteria and Gram-negative bacteria is provided.
  • the aqueous liquid formulation of the present invention, in which the precipitation and chemical decomposition of the compound of the formula (1) is suppressed, is industrially useful.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP16803454.4A 2015-06-02 2016-06-02 Médicament aqueux Withdrawn EP3305295A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015111863 2015-06-02
PCT/JP2016/066410 WO2016195020A1 (fr) 2015-06-02 2016-06-02 Médicament aqueux

Publications (2)

Publication Number Publication Date
EP3305295A1 true EP3305295A1 (fr) 2018-04-11
EP3305295A4 EP3305295A4 (fr) 2019-02-20

Family

ID=57440501

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16803454.4A Withdrawn EP3305295A4 (fr) 2015-06-02 2016-06-02 Médicament aqueux

Country Status (4)

Country Link
US (1) US10206917B2 (fr)
EP (1) EP3305295A4 (fr)
JP (1) JP6675396B2 (fr)
WO (1) WO2016195020A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305296A4 (fr) * 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. Formulation liquide aqueuse
EP3305294A4 (fr) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. Médicament aqueux

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63188626A (ja) 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
JP2832535B2 (ja) 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
AU647772B2 (en) 1989-12-29 1994-03-31 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
FR2665635A1 (fr) 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
CN1104899C (zh) 1995-12-21 2003-04-09 美国辉瑞有限公司 可注射喹诺酮制剂
ID21415A (id) 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE10048510A1 (de) 2000-09-29 2002-05-16 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
JP4384402B2 (ja) * 2001-11-30 2009-12-16 富山化学工業株式会社 デスフルオロピリドンカルボン酸系化合物を含有する水溶液剤およびその粉末化物並びにそれら製造方法
US7514451B2 (en) * 2003-09-10 2009-04-07 Kyorin Pharmaceutical Co., Ltd. 7-(4-Substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative
ZA200700844B (en) 2004-07-02 2009-07-29 Daiichi Seiyaku Co Quinolone-containing medicinal composition
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
SA112330992B1 (ar) * 2011-11-10 2015-09-13 كيورين فارماسوتيكال كو.، ليمتد صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي
WO2014174848A1 (fr) * 2013-04-25 2014-10-30 杏林製薬株式会社 Comprimé
US9687453B2 (en) 2013-04-25 2017-06-27 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EP2990038B1 (fr) 2013-04-25 2019-11-20 Kyorin Pharmaceutical Co., Ltd. Composition pharmaceutique solide
US10406149B2 (en) * 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
US10617684B2 (en) * 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3305296A4 (fr) * 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. Formulation liquide aqueuse
EP3305294A4 (fr) * 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. Médicament aqueux
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug

Also Published As

Publication number Publication date
US10206917B2 (en) 2019-02-19
JPWO2016195020A1 (ja) 2018-03-29
US20180169088A1 (en) 2018-06-21
JP6675396B2 (ja) 2020-04-01
EP3305295A4 (fr) 2019-02-20
WO2016195020A1 (fr) 2016-12-08

Similar Documents

Publication Publication Date Title
US20200237745A1 (en) Aqueous drug
JP6349435B2 (ja) ７−｛（３ｓ、４ｓ）−３−［（シクロプロピルアミノ）メチル］−４−フルオロピロリジン−１−イル｝−６−フルオロ−１−（２−フルオロエチル）−８−メトキシ−４−オキソ−１、４−ジヒドロキノリン−３−カルボン酸の結晶
EP2990038B1 (fr) Composition pharmaceutique solide
TW201706249A (zh) 製造喹啉化合物之方法及包含該化合物之醫藥組合物
EP3305295A1 (fr) Médicament aqueux
US10406149B2 (en) Aqueous liquid formulation
JP6031217B1 (ja) 水性液剤
JP6031216B1 (ja) 水性液剤
JP2021102642A (ja) 結晶性β−ラクタマーゼ阻害剤
EP4177257A1 (fr) Succinate de composé octahydrothiénoquinoline et cristaux de celui-ci
CN109053702A (zh) 一种阿法替尼类似物及其制备方法和用途
JP2010013356A (ja) 結晶性カルバペネム化合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20171221

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190118

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 31/04 20060101ALI20190114BHEP

Ipc: A61K 31/4709 20060101AFI20190114BHEP

Ipc: A61K 9/08 20060101ALI20190114BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220104